Abeona Therapeutics (ABEO) reported second-quarter 2026 net ZEVASKYN revenue of $11.4 million, up 31% from $8.7 million in the first quarter. The company reported a net loss of $20.2 million, or $0.35 per basic and diluted share.
Five patients were treated with ZEVASKYN during the quarter, with revenue recognized for four treatments. Abeona had $146.8 million in cash, cash equivalents and short-term investments as of June 30, 2026.
- Total revenue was $11.38 million for the quarter ended June 30, 2026.
- R&D expense was $5.0 million, while selling, general and administrative expense was $15.8 million.
- Three additional ZEVASKYN treatments were completed in the third quarter to date, bringing total completed treatments since launch to 12.
- The qualified treatment center network expanded to seven sites nationwide.
- CMS New Technology Add-On Payment status for ZEVASKYN becomes effective October 1, 2026.
$ABEO Insider Trading Activity
$ABEO insiders have traded $ABEO stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $ABEO stock by insiders over the last 6 months:
- VISHWAS SESHADRI (Chief Executive Officer) has made 0 purchases and 2 sales selling 97,956 shares for an estimated $604,810.
- JOSEPH WALTER VAZZANO (Chief Financial Officer) has made 0 purchases and 3 sales selling 27,143 shares for an estimated $186,644.
- ERIC CROMBEZ sold 26,143 shares for an estimated $144,636
- CHRISTINE BERNI SILVERSTEIN sold 18,160 shares for an estimated $103,695
- MADHAV VASANTHAVADA (Chief Commercial Officer) sold 12,606 shares for an estimated $87,784
- BRENDAN M. O'MALLEY (SVP, Chief Legal Officer) sold 12,050 shares for an estimated $83,912
- MARK ALVINO sold 6,500 shares for an estimated $35,462
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ABEO Hedge Fund Activity
We have seen 73 institutional investors add shares of $ABEO stock to their portfolio, and 37 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 3,047,985 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $13,654,972
- ONEDIGITAL INVESTMENT ADVISORS LLC added 1,653,024 shares (+inf%) to their portfolio in Q2 2026, for an estimated $10,215,688
- GOLDMAN SACHS GROUP INC added 628,435 shares (+125.1%) to their portfolio in Q1 2026, for an estimated $2,815,388
- ABERDEEN GROUP PLC removed 616,413 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $2,761,530
- CABLE CAR CAPITAL, LP added 507,329 shares (+20.3%) to their portfolio in Q1 2026, for an estimated $2,272,833
- PROPEL BIO MANAGEMENT, LLC added 499,119 shares (+60.1%) to their portfolio in Q1 2026, for an estimated $2,236,053
- JAIN GLOBAL LLC removed 366,067 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $1,639,980
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
